Today, a Director at Ocular Therapeutix (OCUL), Heier Jeffrey, bought shares of OCUL for $99.6K.
This recent transaction increases Heier Jeffrey S.’s holding in the company by 100% to a total of $97.2K. In addition to Heier Jeffrey, one other OCUL executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Ocular Therapeutix’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $504K and GAAP net loss of $17.4 million. In comparison, last year the company earned revenue of $487K and had a GAAP net loss of $13.1 million. Currently, Ocular Therapeutix has an average volume of 525.9K.
Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $14.00, reflecting a 244.8% upside. Starting in May 2018, OCUL received 33 Buy ratings in a row. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy OCUL with a $11 price target.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
